SYCP2L

Across TCGA pan-cancer cohorts, SYCP2L Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated SYCP2L data layer compared with 21 for mass-spec protein.

The strongest signal is observed in thyroid carcinoma (THCA), where higher SYCP2L Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SYCP2L expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

THCA, UCEC, and STAD are the cancer types where SYCP2L Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THCA	OS	Median	All	0.150	0.951	<.001	36	view →
UCEC	DFS	Median	All	0.972	0.621	.005	26	view →
STAD	OS	Median	III,IV	0.001	0.633	<.001	24	view →
SARC	OS	Median	All	0.032	0.861	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.495	0.200	.007	5	view →
COAD	OS	Median	All	0.674	0.878	.010	3	view →
HNSC	OS	Median	All	0.513	0.752	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

SYCP2L–THCA (OS)

Open the THCA breakdown →